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Introduction: Malignant pericardial effusion (MPE) causes cardiac
tamponade and an extremely poor outcome unless it is well con-
trolled. The effect of pericardial drainage and the intra-pericardial
instillation of bleomycin on the control of MPE was examined in
this prospective multi-institutional phase II trial.
Methods: In eligible patients with cytologically defined MPE re-
sulting from non-small cell lung cancer, the pericardial effusion of
such cases was continuously drained. After complete drainage, 10
mg of bleomycin was then locally instilled via a catheter. The
catheter was then removed if the total amount of drainage was less
than 30 ml/day. If the catheter could not be removed within 5 days
after treatment, bleomycin was administered one more time.
Results: Among the 22 patients who entered this trial, the tube
drainage catheter was successfully removed from 17 patients with
one instillation, whereas four required such instillation twice and
one required such instillation three times. No severe adverse events
were observed, except for constrictive pericarditis, which resulted in
the treatment-related death of one patient. The control rate of
pericardial effusion was 95%  0.09 (95% confidence interval). No
restoration of pericardial effusion was observed during the fol-
low-up period or until death from any cause. Median survival time
from the beginning of the protocol was 17.9 weeks.
Conclusions: Pericardial drainage followed by the instillation of
bleomycin was found to be a safe and effective method for the
management of MPE associated with non-small cell lung cancer.
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Malignant pericardial effusion (MPE) was observed inapproximately 10% of all patients with malignancy,
and the storage of pericardial effusion can cause cardiac
tamponade, which may be life-threatening. Lung cancer is the
most frequent cause of MPE. In a review by Fraser et al.,1 14
of 19 patients (74%) presenting with tamponade had a known
pulmonary primary tumor, with adenocarcinoma documented
in 13 of 18 patients (72%). Shepherd et al. also reported 27 of
58 (47%) patients with MPE in whom lung cancer was the
primary malignancy.2 Until recently, the intra-pericardial
instillation of several agents, including tetracyclin,2,3 doxy-
cycline,3,4 streptococcal preparation,5 platinum deriva-
tives,6–9 5-fluorouracil,10 thiotepa,11–13 antracyclines,14 vin-
blastine15 and bleomycin, was reported to be effective for the
control of MPE.4,16 Most of these agents, however, are
accompanied by adverse effects such as pain, fever, nausea,
or leukocytopenia. We recently reported a simple program to
manage MPE by continuous tube drainage and the subsequent
local instillation of low-dose bleomycin in patients with
non-small cell lung cancer (NSCLC).17 This procedure al-
lowed for the complete control of MPE without any adverse
events. In addition to this report and based on the findings of
our previous prospective single-institutional study, which
clearly indicated that the effect of drainage alone was inad-
equate and therefore the sclerosing or anti-cancer activity of
intra-pericardial bleomycin administration was required to
control MPE in patients with NSCLC, we herein confirm and
assess the effect of this treatment in a multicenter setting.
MATERIALS AND METHODS
Eligibility
This multi-institutional phase II trial, as proposed by
the Kyushu Yamaguchi Thoracic Oncology Group, had ap-
propriate institutional ethical review board approval, and all
patients provided written, informed consent according to
institutional guidelines before entry. Eligible patients had a
histologically or cytologically confirmed diagnosis of
NSCLC, symptoms of cardiac tamponade caused by MPE
cytologically defined as a result of NSCLC, any age, any
ECOG performance status, adequate hematological parame-
ters with a total leukocyte count 3,000/l, platelet count
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75,000/l, adequate renal function showing serum creati-
nine less than two times the upper limit of normal, and an
expected survival period of more than 4 weeks if cardiac
tamponade could be controlled. Prior treatment including
surgery, systemic chemotherapy, and radiotherapy was per-
mitted. However, systemic chemotherapy or tyrosine kinase
inhibitor (TKI) was not permitted during effusion drainage
and the sclerosing procedure. Pregnant or lactating women
and patients with serious medical disorders incompatible with
the study were also considered ineligible.
Design of Treatment
A medicut catheter (14 gauge) was placed in the peri-
cardial space through an echo-guided inserted sheath. Any
observed pericardial effusion was then allowed to drain
naturally by gravity during a 24-hour period. The effusion
was completely drained, and 10 mg of bleomycin dissolved in
20 ml of saline was instilled into the pericardial cavity via the
catheter. The catheter was then clamped for 6 hours after the
administration of bleomycin. When the catheter was re-
opened, any remaining effusion was thereafter naturally
drained until it reached less than 30 ml/day, at which point
the catheter was removed. For patients from whom the
catheter could not be removed within 5 days after the treat-
ment, bleomycin was administered one more time. Systemic
chemotherapy or TKI was permitted if there were no symp-
toms as a result of pericardial effusion or no re-accumulation
of effusion for more than 2 weeks after the removal of the
catheter.
Criteria of Response
The response criteria for malignant pericardial effusion
of Paladine et al.18 and the United Kingdom Multi-Centre
Study19 were adopted in this study. A response is defined as
follows: a complete remission (CR) meant that there was no
re-accumulation of fluid within the first 30 days as deter-
mined by a clinical examination, chest radiogram, or
echogram. A partial remission (PR) was defined as a minimal
fluid recurrence not requiring aspiration within the initial
30-day evaluation period. Those patients who had to be
re-aspirated within less than 30 days were classified as
treatment failures. The evaluation was discontinued when
either the effusion recurred or the patient died. The control
rate was calculated using the following formula: the number
of CR plus the PR/accrual number. The toxicity criteria were
based on the National Cancer Institute common toxicity
criteria (NCI-CTC), version 2.0 (http://ctep.info.nih.gov/).
All toxicities were reported within the initial 30-day evalua-
tion period even if systemic chemotherapy was given.
End Points and Sample Size Consideration
The primary end point of this study was to determine
the control rate of MPE among patients who underwent this
treatment. The secondary end points were the duration of
MPE in the control, overall survival, and toxicity. The sample
size was calculated based on an expected control rate of 95%
and an acceptable lowest rate of 70%, with alpha and beta
errors of 0.05 and 0.2, respectively; a total of 19 patients were
required using the one-sample multiple testing procedure of
Fleming.20 In this design, when the number of controls
exceeds 16 of 19 cases, this leads to the rejection of the
hypothesis that the true control rate is less than 70%. The
accrual and follow-up periods after accrual closure were 2
years and 1 year, respectively.
RESULTS
From January 1999 to October 2004, 22 patients were
enrolled into this study. The patient characteristics are shown
in Table 1. The patients ranged from 42 to 79 years of age
(mean, 62 years) and consisted of 16 men and six women,
with 21 adenocarcinomas and one large cell carcinoma.
Twenty patients who had no prior surgery included five stage
IIIB and 15 stage IV, and two patients who had undergone
surgery for primary diseases. The drainage catheter was
successfully removed from all patients. Bleomycin was ad-
ministered once in 17 patients, twice in four, and three times
in only one. The period from the instillation of bleomycin
until the removal of the catheter ranged from 2 to 20 days,
with a median of 5 days. No patients experienced any severe
adverse events associated with the pericardial instillation of
bleomycin, except for treatment-related death in only one
patient as a result of constrictive pericarditis. Constrictive
pericarditis occurred 2 weeks after the administration of
bleomycin. The control rate (CR or PR) of pericardial effu-
sion was 95%  0.09 (95% confidence interval). No resto-
ration of pericardial effusion manifesting cardiac tamponade
was observed during the follow-period or until the death from
any cause. After the control of the pericardial effusion, 11
patients were administered systemic chemotherapy (plati-
num-based for six, non-platinum for two, and gefitinib for
three), and the overall response rate was 9.1% (PR in only
one patient using doublet chemotherapy consisting of cispla-
tin and docetaxel). The median survival time was 17.9 weeks,
as shown in Figure 1.
DISCUSSION
A prospective study to test the effectiveness of a
regimen to control MPE resulting from a single primary
disease may be difficult to complete because the registra-
tion of an adequate number of patients is difficult to
achieve. To our knowledge, the present study is the first to
TABLE 1. Profile of Patients
n
Mean age (yr) 62 (42–79)
Gender
Male 16
Female 6
Cell type
Adenocarcinoma 21
Large cell carcinoma 1
Stage
IIIB 5
IV 15
Recurrent 2
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evaluate the treatment of MPE resulting from NSCLC,
which is the most prevalent cause as the primary disease,
and the patients exhibited excellent results in a multicenter
phase II trial (Table 2).
Our previous pilot study revealed the efficacy of drain-
age and the subsequent instillation of bleomycin in the
control of MPE associated with NSCLC,17 however, it re-
mains unclear as to whether intra-pericardial drainage is
sufficiently effective. Kopecky et al. reported that catheter
drainage was sufficient for the control of benign pericardial
effusion.21 MPE may be generated by the process of the
lymphatic occlusion of the mediastinum, not only by the
direct invasion of cancer cells into the intra-pericardial space.
As a result, drainage alone may have a low therapeutic
potential for this severe oncological problem. In our previous
prospective single-institutional study, however, the respective
efficacy rate of pericardial drainage alone and the intra-
pericardial instillation of bleomycin was 18.2% (2 of 11) and
100% (9 of 9), and the respective rate of recurrent storage was
50% and 0%, respectively (data not published). These results
clearly indicate that the effect of drainage alone was inade-
quate; therefore, the sclerosing or anti-cancer activity of
bleomycin was required (Table 3).
There were few adverse events of grade 2 or greater
associated with the local instillation of bleomycin. A low-
grade fever (grade 1) was observed in six patients. However,
the optimal dosage of bleomycin remains to be elucidated
because four patients required two administrations for a total
of 20 mg, and the remaining patient needed three bleomycin
injections.
The criteria for removing the intra-pericardial catheter
in this study are most likely generally applicable because the
catheter could be removed within 5 days in all cases, and no
recurrent pericardial effusion was seen even in the long-term
observation of patients who had undergone the intra-pericar-
dial instillation of bleomycin.
In comparison to several reported regimens for the
control of MPE resulting from multiple etiologies based on
analyses of the reported data, a subxiphoid pericardiotomy
showed the best therapeutic efficacy with a control rate of
100%.22,23 Considering the invasiveness and the required
daily management of the surgical drainage for such a proce-
dure, our regimen is thus considered to be safe while also
demonstrating the same efficacy.
In conclusion, the intra-pericardial instillation of bleo-
mycin after catheter drainage is therefore considered to be
highly safe and effective for the control of MPE associated
with NSCLC.
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